Development and Validation of Staging Systems for AA Amyloidosis CONCLUSIONS: We identified and validated biomarker-based staging systems for overall survival and kidney failure in AA … ← Navigating the misty lands of monocytosis Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043 patient/years analysis →